FundedIQ
Biotechnology

Ventuno Biotech

Ventuno Biotech is a biotech company that is developing innovative cancer therapies.

ventuno-biotech.com Lyon, France 1-10 employees
Total raised
$2.3M
Rounds
1
Latest
Seed
Nov 2025

Ventuno Biotech is a biotech company that is developing innovative cancer therapies.

Ventuno Biotech has raised $2.3M across 1 round. Its most recent round was a Seed of $2.3M in Nov 2025. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Nov 24, 2025
Seed
$2.3M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Ventuno Biotech is featured in

Similar companies

Repair Biotechnologies

Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading platform.

Venture - Series Unknown $5.3M
Skeletalis

Skeletalis develops precision medicines targeting bone loss to treat osteoporosis and prevent fractures safely.

Venture - Series Unknown $8.0M
T-Therapeutics

T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.

Series A $32.0M
Azalea Therapeutics

Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.

Series A $65.0M
Braveheart Bio

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.

Series A $185M
Adaptam Therapeutics

Adaptam Therapeutics is at the forefront of next-generation cancer immunotherapies

Pre-Seed $3.5M
Zag Bio

Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.

Series A $80.0M
Excellergy

Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases.

Series A $70.0M
Curadel Surgical Innovations

Curadel Surgical Innovations oversees the complete process of Curadel's FLARE contrast agents for image-guided surgery.

Venture - Series Unknown $14.5M
Cartography Biosciences

Cartography is an oncology company that develops cancer immunotherapies that target novel and highly specific tumor antigens.

Series B $67.0M
Athernal Bio

Treating the seeds of cancer

Seed $4.7M
Nuclide Therapeutics

Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.

Seed $6.7M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.